Below are the most recent publications written about "Inflammatory Bowel Diseases" by people in Profiles.
-
David JG, Chute D, Reed B, Saeed S, DeMatteo D, Atay O, Maddux M, Daly B. Assessing the Prevalence of and Risk Factors for Disordered Eating Attitudes and Behaviors in Adolescents With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2022 01 05; 28(1):143-145.
-
Olendzki B, Bucci V, Cawley C, Maserati R, McManus M, Olednzki E, Madziar C, Chiang D, Ward DV, Pellish R, Foley C, Bhattarai S, McCormick BA, Maldonado-Contreras A. Dietary manipulation of the gut microbiome in inflammatory bowel disease patients: Pilot study. Gut Microbes. 2022 Jan-Dec; 14(1):2046244.
-
Janardhana P, Al-Kadhi S. A review of ophthalmic manifestations of inflammatory bowel disease and associated treatments. Curr Opin Ophthalmol. 2021 Nov 01; 32(6):549-554.
-
Suri K, Bubier JA, Wiles MV, Shultz LD, Amiji MM, Hosur V. Role of MicroRNA in Inflammatory Bowel Disease: Clinical Evidence and the Development of Preclinical Animal Models. Cells. 2021 08 26; 10(9).
-
Wyant T, Yang L, Lirio RA, Rosario M. Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease. J Clin Pharmacol. 2021 09; 61(9):1174-1181.
-
Chengxiao Y, Dongmei W, Kai Z, Hou L, Xiao H, Ding T, Liu D, Ye X, Linhardt RJ, Chen S. Challenges of pectic polysaccharides as a prebiotic from the perspective of fermentation characteristics and anti-colitis activity. Carbohydr Polym. 2021 Oct 15; 270:118377.
-
Sun W, Fennimore B, Beaulieu DB, Arsenescu R, Stein AC, Chen J, Lin T, McKnight S, Kadali H, Rosario M, Lirio RA. Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease. Clin Pharmacokinet. 2021 06; 60(6):811-818.
-
Loftus EV, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, Danese S, D'Haens G, Rubin DT, Shafran I, Parfionovas A, Rogers R, Lirio RA, Vermeire S. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365.
-
Hoang CM, Davids JS, Maykel JA, Flahive JM, Sturrock PR, Alavi K. Not All Discharge Settings Are Created Equal: Thirty-Day Readmission Risk after Elective Colorectal Surgery. Dis Colon Rectum. 2020 09; 63(9):1302-1309.
-
Aidlen JT. Response regarding: Risk Factors for Venous Thromboembolism in Children and Young Adults With Inflammatory Bowel Disease. J Surg Res. 2020 03; 247:296.